Dr. Helen Hou joined the Department of Small Molecule Pharmaceutical Sciences at Genentech (South San Francisco, California) in 2015. In her current role as a Senior Scientist, she is responsible for drug product development to allow fast-entry into human and the definition of market-image formulation/process. Prior to joining Genentech, Helen worked in several industrial positions at Allergan (2013 â€“2015), AbbVie (2008 â€“ 2013), and Amgen (2006 â€“ 2007), specialized in development of oral solid dosage forms and sterile product for ophthalmology. Helen received her Ph.D. in materials science and engineering from the University of Minnesota in 2006, where she did research in development of novel intranasal formulation for the treatment of epilepsy. Her primary research interests include understanding the effect of solubilizing additives on the manufacturability and release behavior of high-energy solids, and designing in vitro models for the prediction of in vivo performance of supersaturating solid dosage forms.